Literature DB >> 32552363

Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.

Seth N Levin1, Chimere Ezuma1, Libby Levine1, Wendy S Vargas1, Rebecca S Farber1, Philip L De Jager1, Claire S Riley1.   

Abstract

Entities:  

Year:  2020        PMID： 32552363     DOI： 10.1177/1352458520927631

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  3 in total

Review 1.  Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk.

Authors:  Hans-Peter Hartung; Jan Mares; Sven G Meuth; Thomas Berger
Journal:  Neurotherapeutics       Date:  2021-09-03       Impact factor: 7.620

2.  Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.

Authors:  Kévin Bigaut; Laurent Kremer; Thibaut Fabacher; Guido Ahle; Mathilde Goudot; Marie Fleury; Claude Gaultier; Sylvie Courtois; Nicolas Collongues; Jérôme de Seze
Journal:  J Neurol       Date:  2022-01-04       Impact factor: 4.849

Review 3.  Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Authors:  Serena Brancati; Lucia Gozzo; Laura Longo; Daniela Cristina Vitale; Filippo Drago
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.